Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2026-05-29 Delisting Announcement
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Delisting Announcement Classification · 93% confidence The document is a Form 8-K current report containing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. It describes receipt of a NYSE American delisting notice, compliance requirements, and potential delisting proceedings. This clearly matches the “Delisting Announcement” category.
2026-05-29 English
10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
Annual Report
2026-03-30 English
8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC by Actinium Pharmaceuticals, Inc. It amends a previous Form 8-K that reported the final voting results of the company's Annual General Meeting held on November 26, 2025. The amendment specifically discloses the company's decision on the frequency of future shareholder advisory votes on executive compensation (Say-on-Pay Votes). The content focuses on voting results and shareholder advisory vote frequency decisions, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual report, earnings release, or management discussion, but an official announcement of voting results and related decisions. Therefore, the correct classification is DVA with high confidence.
2026-03-26 English
8-K - ACTINIUM PHARMACEUTICALS, INC. (0001388320) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 11, 2026, reporting a change in senior management: the resignation of the Chief Financial Officer and the appointment of the CEO as the new principal financial officer. The content focuses on management changes and does not contain financial statements or detailed financial analysis. Therefore, it fits the category of Board/Management Information (MANG). The document length is 5594 characters, which is sufficient to contain substantive information about the management change rather than a brief announcement. Hence, the classification is MANG with high confidence.
2026-02-13 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 26, 2025, by Actinium Pharmaceuticals, Inc. It reports on the results of the company's 2025 annual meeting of stockholders, including the election of Class III directors and voting results on various proposals such as ratification of the independent auditor and executive compensation. The content focuses on changes in the board of directors and voting outcomes from the annual meeting. There is no detailed financial data or comprehensive report content, but rather an announcement of director elections and voting results. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' which covers official results from shareholder votes at any general meeting (AGM or EGM). Therefore, the appropriate classification is DVA with high confidence.
2025-11-26 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2025
2025-11-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.